


# AMENDMENTS TO THE CLAIMS

Please rewrite the claims as follows:

## 1. (Currently Amended) Compounds of Formula (I)




wherein

A is a group of the formula  $-\text{C}(\text{CH}_3)=\text{CHR}^5$  or  $-\text{CH}=\text{CHR}^5$ , wherein R<sup>5</sup> is a heteroaryl- or a heteroarylalkyl group, ~~heteroalkyl-, heterocycloalkyl-, heteroalkyleycloalkyl-, heteroaryl- or heteroarylalkyl- group;~~

U is hydrogen, halogen, an C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl-, trifluoromethyl or COOH-~~heteroalkyl-, heterocycloalkyl-, heteroalkyleycloalkyl-, heteroaryl- or heteroarylalkyl-~~ group;

G-E is selected from the following groups,



or is part of an optionally substituted phenyl ring,

R<sup>1</sup> is a C<sub>1</sub>-C<sub>4</sub>-alkyl-, a C<sub>2</sub>-C<sub>4</sub>-alkenyl-, a C<sub>2</sub>-C<sub>4</sub>-alkynyl- or a C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-group,

V-W is a group of formula CH<sub>2</sub>CH or CH=C,

X is oxygen or a group of the formula NR<sup>2</sup>, wherein R<sup>2</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl,  
or C<sub>1</sub>-C<sub>4</sub> heteroalkyl,



~~an alkyl-, alkenyl-, alkynyl-, heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcycloalkyl-,  
 heteroalkylcycloalkyl-, heterocycloalkyl-, aralkyl- or heteroarylalkyl-group and~~

R<sup>3</sup> and R<sup>4</sup> independently from each other represent hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl or together are part of a cycloalkyl group with 3 or 4 ring atoms,

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.

2. (Canceled)

3. (Original) Compounds according to claim 1, wherein A is a group of formula (II) or (III)



wherein Q is sulphur, oxygen or NR<sup>7</sup>, wherein R<sup>7</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> heteroalkyl, z is Nitrogen or CH and R<sup>6</sup> is OR<sup>8</sup>, NHR<sup>8</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl or C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> heteroalkyl.


4. (Previously Presented) Compounds according to claim 1, wherein X is oxygen or NH.

5. (Previously Presented) Compounds according to claim 1, wherein  $R^1$  is methyl or ethyl.
6. (Previously Presented) Compounds according to claim 1, wherein  $R^3$  and  $R^4$  are methyl groups.
7. (Previously Presented) Compounds according to claim 1, wherein U is hydrogen, fluorine, methyl, trifluoromethyl or COOH.
8. (Previously Presented) Compounds according to claim 1, wherein G-E is selected from the following groups:



9. (Previously Presented) Compounds according to claim 1, wherein V-W is  $CH_2CH$ .
10. (Previously Presented) Pharmaceutical compositions containing a compound, a pharmacologically acceptable salt, a solvate or a hydrate according to claim 1 or a prodrug of the compound, the salt, the solvate and/or the hydrate and optionally one of more carriers and/or one or more adjuvants and/or one or more diluents.
11. (Currently Amended) Method of treating a disease selected from the group consisting of breast, ovarian, lung and prostate cancer through administering a pharmaceutically effective amount Use of a compound or a pharmaceutical composition according to claim 1 ~~for the treatment of cancer.~~
12. (Canceled)

13. (Withdrawn) Compounds of formula (IVa), (IVb), (Va) and (Vb),



wherein the groups PG independently from each other represent hydrogen or protecting groups.

14. (Withdrawn) Use of a compound according to claim 13 for the synthesis of a compound of formula (I).